BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy

Nov 19, 2026
New Preclinical Findings Show TROP2 Levels May Help Predict REQORSA Treatment Response—and That Modifying TROP2 Expression May Increase Cancer Cell Sensitivity to Gene Therapy. Combined With the Roche Diagnostics Collaboration, Expanding TUSC2 Research and Advancing Clinical Programs, Genprex, Inc. (NAS DAQ: GNPX) Is Building Significant Momentum Across Its Innovative Biotechnology Platform.

AUSTIN, Texas - Nov. 19, 2026 - PRLog -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is bringing another exciting development to its growing gene therapy story with today's November 19 announcement of new preclinical data identifying TROP2 as a potential predictive biomarker for its lead investigational therapy, REQORSA® (quaratusugene ozeplasmid). Presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the research offers important new insights into how TROP2 expression may influence the response of non-small cell lung cancer (NSCLC) to REQORSA.

What makes today's announcement especially interesting is that researchers are investigating more than simply whether TROP2 can identify patients likely to respond. The new findings also suggest that changing TROP2 expression may influence how cancer cells respond to TUSC2 gene therapy, potentially opening another avenue for improving treatment sensitivity.

For Genprex investors, this represents an important addition to an increasingly sophisticated precision-oncology strategy. The company is working to combine its innovative gene therapy platform with biomarker research that could help researchers better understand treatment response and identify patients who may benefit most.

Today's Big News: TROP2 Research Reveals Another Potential Advantage for REQORSA

The November 19 announcement highlights findings from research titled "TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment."

Researchers evaluated multiple NSCLC cell lines and patient-derived organoid models to investigate the relationship between TROP2 expression and response to TUSC2 gene delivery.

The findings were particularly noteworthy:
  • Approximately 50% of the 10 NSCLC cell lines evaluated demonstrated primary resistance to TUSC2 gene delivery.
  • Approximately 50% of the 12 patient-derived organoid models also demonstrated primary resistance.
  • Low TROP2 protein expression was consistently associated with primary resistance across multiple preclinical models.
  • Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial provided additional supporting evidence.

Perhaps the most intriguing aspect involved experiments examining whether changing TROP2 expression could influence treatment sensitivity.

Researchers introduced TROP2 into TROP2-low NSCLC cancer cells, including H460 and H1299 models. This significantly increased TUSC2-induced apoptosis, bringing the response to levels similar to cells naturally expressing higher TROP2.

This is an important scientific observation because it suggests TROP2 may have a role beyond simply identifying tumors that respond differently. Modifying its expression could potentially become another research strategy for enhancing REQORSA treatment.

The company believes these findings could help inform future patient-selection strategies and additional research into improving treatment response.

Roche Diagnostics Collaboration: A Powerful Addition to Genprex's Strategy

One of Genprex's most important strategic developments remains its collaboration with Roche Diagnostics, announced August 3.

The collaboration focuses on validating biomarker assays for non-small cell lung cancer, with particular attention to TROP2 and PTEN.

Roche brings extensive diagnostic expertise to the relationship, while Genprex contributes its developing REQORSA gene therapy platform and growing body of clinical and preclinical research.

The objective is to develop a more refined approach to identifying patients who may be more likely to benefit from REQORSA.

Previous clinical research suggested that higher TROP2 expression and lower PTEN expression were associated with longer progression-free survival in certain NSCLC patient groups.

Today's new findings add another important scientific component to this collaboration by providing additional evidence supporting the investigation of TROP2 as a potential predictive biomarker.

Genprex anticipated completing the Roche-related assay validation studies around the end of 2026, with potential incorporation into its NSCLC clinical program following successful validation.

The combination of Roche's diagnostic capabilities and Genprex's gene therapy research could become an important part of the company's precision-medicine strategy.

REQORSA: Advancing an Innovative Approach to Lung Cancer

At the center of Genprex's oncology platform is REQORSA, also known as quaratusugene ozeplasmid.

The investigational therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.

TUSC2 expression is reduced or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, making it an important target for investigation.

REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression, including MAPK and mTOR signaling, cell-cycle regulation and programmed cancer-cell death.

Genprex is advancing two important clinical initiatives:

Acclaim-1: Evaluating REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.

Acclaim-3: Evaluating REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both programs have received FDA Fast Track designation, while the small cell lung cancer program has also received Orphan Drug Designation.

New TUSC2 Research Expands the Scientific Story

Genprex has also been generating interest through its sponsored research collaboration with Meharry Medical College.

Recent research has examined TUSC2's role in cellular resilience, mitochondrial function and biological processes associated with aging.

On November 5, the company highlighted patient-derived research involving blood samples from 11 lung cancer patients receiving REQORSA. Researchers identified changes in gene-expression patterns associated with mitochondrial adaptation, autophagy, cellular maintenance and protein quality control.

These findings add another dimension to the understanding of TUSC2's biological activity in humans and complement the company's broader scientific investigation.

Diabetes Gene Therapy Adds Another Development Opportunity

Beyond oncology, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.

The approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.

In August, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This provides another important development program as the company works toward future clinical research.

The Road Ahead: Important Catalysts for GNPX Investors

Genprex has several important developments to watch as 2026 progresses:
  • Continued investigation of TROP2 as a potential predictive biomarker for REQORSA.
  • Further research into whether TROP2 modulation can enhance treatment sensitivity.
  • Anticipated completion of Roche Diagnostics biomarker assay validation.
  • Continued advancement of the Acclaim-1 and Acclaim-3 clinical programs.
  • Additional TUSC2 research and diabetes gene therapy development.

Genprex Is Building an Intriguing Precision Gene Therapy Platform

Today's November 19 announcement adds another important milestone to Genprex's developing story. The TROP2 findings are particularly interesting because they suggest two potential opportunities: identifying patients more likely to respond to REQORSA and investigating whether changing TROP2 expression could increase treatment sensitivity.

Combined with the Roche Diagnostics collaboration, these findings strengthen the scientific foundation behind Genprex's precision-oncology ambitions.

The company's continued TUSC2 research, advancing lung cancer clinical programs and separate diabetes gene therapy initiative provide multiple areas of development to follow.

For investors watching emerging biotechnology opportunities, Genprex is building an increasingly compelling story around innovative gene therapy, strategic diagnostic collaboration and personalized cancer treatment. With today's new TROP2 findings adding another exciting dimension to REQORSA, GNPX has important scientific milestones ahead as it works to translate its research into meaningful clinical progress.

For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: [email protected]
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
CorporateAds
***@gmail.com

Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy | More news from this source

Press release distribution by PRLog

More News

ICJ: Myanmar committed genocide against Rohingya
Nov 19, 2026
ICJ: Myanmar committed genocide against Rohingya

Court orders reparations, refugee returns, and accountability for atrocities.

Vietnam's top leader To Lam meets US President Trump on APEC sidelines in Shenzhen
Nov 19, 2026
Vietnam's top leader To Lam meets US President Trump on APEC sidelines in Shenzhen

Party General Secretary and President To Lam called on the U.S. to support Vietnam in successfully hosting APEC 2027 when he met President Donald Trump on the sidelines of the APEC 2026 Economic Leaders' Week in Shenzhen, China, on Thursday.

Anwar impatient over probe into drug smuggling involving Air Force personnel
Nov 19, 2026
Anwar impatient over probe into drug smuggling involving Air Force personnel

He says authorities need more time, but decisive action cannot wait.

PAS rep among 5 new faces appointed as Malacca exco
Nov 19, 2026
PAS rep among 5 new faces appointed as Malacca exco

Umno gets 8 posts including CM - with MCA, MIC and PAS receiving one each.

Malaysia to review AI chip shipments for illegal re-exports, says deputy minister
Nov 19, 2026
Malaysia to review AI chip shipments for illegal re-exports, says deputy minister

PARLIAMENT | Customs and enforcement agencies will assist in the probe.

Four unfinished projects could put Christmas opening of Vietnam's largest airport Long Thanh at risk
Nov 19, 2026
Four unfinished projects could put Christmas opening of Vietnam's largest airport Long Thanh at risk

With just over a month to go before its planned commercial opening on Dec. 24, Long Thanh International Airport still has large volumes of work to finish, from its passenger terminal and internal roads to acceptance checks and licensing.

UN top court says Myanmar committed genocide against Rohingya
Nov 19, 2026
UN top court says Myanmar committed genocide against Rohingya

The United Nations’ top court has ruled that Myanmar “committed genocide” against the Rohingya population in a 2017 crackdown that left at least 10,000 of its members dead and then drove vast numbers into Bangladesh. In a landmark decision on Thursday, Yuji Iwasawa, president of the International Court of Justice (ICJ) at The Hague, gave the legal basis for the ruling pegged to the 1951 Convention on the Prevention and Punishment of the Crime of Genocide. “The Republic of the Union of Myanmar...

PM: Najib’s house arrest order may have been declassified for court
Nov 19, 2026
PM: Najib’s house arrest order may have been declassified for court

Anwar, speaking in Shenzhen, says Putrajaya will provide an update soon.

MPs decry stray animal abuse, urge more humane management by govt
Nov 19, 2026
MPs decry stray animal abuse, urge more humane management by govt

PARLIAMENT | Calls include neutering, affordable reclamation, stricter enforcement.

Indonesia’s forest protection plan praised by Leonardo DiCaprio. Will it work?
Nov 19, 2026
Indonesia’s forest protection plan praised by Leonardo DiCaprio. Will it work?

Indonesia’s pledge to halt forest clearing for food production and repurpose degraded land instead has drawn praise from actor Leonardo DiCaprio, who called it “historic”, but green experts argue the plan is vague and may even weaken vulnerable ecosystems. Speaking at the COP31 climate summit in Turkey last week, Hashim Djojohadikusumo, President Prabowo Subianto’s brother and special envoy for climate and energy, reiterated Jakarta’s intention to refrain from expanding agricultural activities...

Raub MP: Chinese lettering on heritage hall does not threaten Malay language
Nov 19, 2026
Raub MP: Chinese lettering on heritage hall does not threaten Malay language

'Chinese lettering reflects identity, history of the more than century-old institution.'

'See you tomorrow,' says Ismail after days of uncertainty over MB 'resignation'
Nov 19, 2026
'See you tomorrow,' says Ismail after days of uncertainty over MB 'resignation'

He is expected to have an audience with Tuanku Muhriz on Friday.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

KL Explore

KL Explore is a Travel site for tourist or locals who would love to experience the multicultural atmosphere in Malaysia.

ABOUT US

Contact us: sales[at]klexplore.com